)
)
Clovis Oncology Investor Relations Material
Latest events
Q2 2022
Clovis Oncology
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Clovis Oncology Inc
Access all reports
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company's clinical trial programs comprise three drug candidates designed to inhibit the growth of cancer tumors. Its lead product candidate is NDA 20-538 for metastatic adenocarcinoma of the pancreas; and other preclinical assets include NK-1 receptor antagonists for the treatment of inflammatory bowel disease; glio-selectins for the treatment of glioblastoma multiforme; and JTK inhibitors for multiple indications. Clovis Oncology markets its products through a limited direct sales force in the majority of its markets. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado.
Latest articles
)
Mercado Libre: The Digital Backbone of Latin America
From shopping to logistics and fintech, Mercado Libre is shaping the digital transformation of Latin America.
3 Jan 2025
)
House of Pinault: The History and Business of Kering and Gucci
Kering is a luxury group under the Pinault family's leadership, managing iconic brands like Gucci, Saint Laurent, and Bottega Veneta.
19 Dec 2024
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
Ticker symbol
CLVS
Country
🇺🇸 United States